Recent setbacks in the stock market are particularly troubling for public stem cell companies, say analysts. With government funding to the field tightly restricted, the public markets have been a key source of funds for these developers. But investors tend to take a particularly skeptical view of early-stage development programs that are hard to understand. Merchant banker Steve Burrill told MarketWatch, though, that there are a number of potential sources of cash for stem cell companies around the world.
- read the report from MarketWatch